BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107

Overview


2024/07/26 22:15:43					
Price 8.30 CAD					
Difference	0	2.09% (0.17)			

General attributes				
ISIN	CA0717341071			
Symbol	ВНС			
Exchange	Toronto Stock Exchange			
Currency	CAD			
Sector	Other			
Security type	Stock			
Market cap (m)	2,025 EUR			
Benchmark	S&P/TSX 60 INDEX			

Market data	
Bid (Bid size)	8.25 CAD (1,000)
Ask (Ask size)	8.34 CAD (900)
Open	8.15 CAD
High	8.35 CAD
Low	7.87 CAD
Close (prev. day)	8.13 CAD
VWAP	8.17102 CAD
Volume (pcs)	716,161
Trading volume	5,851,765.81
Number of trades	4,176
Last size	200

Futures and Options	
Related Futures	15
Related Options	-





Information about previous performance does not guarantee future performance. **Source:** FactSet

Recent research

on sector			
Date		Headline	Download
2024/07/24	80 Jan 80 Jan	Global Equity Ratings	
2024/07/12	20 L20 27 FS	Global Equity Ratings	
2024/06/21	80 Jan 80 Jan	Global Equity Ratings	
2024/06/14	20 L20 27 FS	Global Equity Ratings	
2024/05/29	80. J.B. 80. T.B.	Global Equity Ratings	.≛.




Details

2024/07/26 22:15:43					
Price					
8.30 CAD					
Difference	0	2.09% (0.17)			

General attributes				
ISIN	CA0717341071			
Symbol	ВНС			
Exchange	Toronto Stock Exchange			
Currency	CAD			
Sector	Other			
Security type	Stock			
Market cap (m)	2,025 EUR			
Benchmark	S&P/TSX 60 INDEX			

Market data	
Bid (Bid size)	8.25 CAD (1,000)
Ask (Ask size)	8.34 CAD (900)
Open	8.15 CAD
High	8.35 CAD
Low	7.87 CAD
Close (prev. day)	8.13 CAD
VWAP	8.17102 CAD
Volume (pcs)	716,161
Trading volume	5,851,765.81
Number of trades	4,176
Last size	200

Performance and Risk						
	6m 1Y 3Y					
Perf (%)	-24.61%	-33.60%	-76.88%			
Perf (abs.)	-2.71	-4.20	-27.60			
Beta	1.47	1.41	1.79			
Volatility	54.33	47.20	74.15			



Information about previous performance does not guarantee future performance. $\textbf{Source:} \ \ \textbf{FactSet}$

Price data	
Ø price 5 days Ø volume 5 days (pcs.)	9.06 CAD (1,081,595)
Ø price 30 days Ø volume 30 days (pcs.)	9.55 CAD (478,883)
Ø price 100 days Ø volume 100 days (pcs.)	10.63 CAD (404,167)
Ø price 250 days Ø volume 250 days (pcs.)	10.73 CAD (359,028)
YTD High date	15.43 CAD (2024/04/03)
YTD Low date	5.45 CAD (2024/07/24)
52 Weeks High date	15.43 CAD (2024/04/03)
52 Weeks Low date	5.45 CAD (2024/07/24)
or fronto rott date	0.40 OAD (2024/01/24)

All listings for BAUSCH HEALTH COMPANIES INC.					
Exchange 🖨	Date	Time	Price	Trading volume (mio.)	Number of trades
Tradegate	2024/07/ 26	22:26	5.522 EUR	0.00	6
Toronto Stock Exchange	2024/07/ 26	22:15	8.30 CAD	5.85	4,176
Stuttgart	2024/07/ 26	11:05	5.365 EUR	0.00	4
SIX Swiss Exchange	2019/06/ 28	17:35	24.11 CHF	0.00	1
NYSE	2024/07/	22:00	5.99 USD	30.75	23,900



	26				
Munich	2024/07/ 26	08:02	5.472 EUR	0.00	1
Frankfurt	2024/07/ 26	08:12	5.355 EUR	0.00	2
Duesseldorf	2024/07/ 26	08:10	5.346 EUR	0.00	3
Berlin	2024/07/ 26	08:02	5.352 EUR	0.00	3



Company profile

Company Logo

BAUSCH Health

Contact Details

BAUSCH HEALTH COS. INC.

_ _

2150 St. Elzéar Boulevard West - H7L 4A8 Laval

Telefon: +1-514-744-6792

Fax: + E-mail: -

PDF Downloads

Company report: BAUSCH HEALTH COMPANIES INC.

đ.

Company Profile

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Members of Management Board	
Thomas Appio	Chairman of Managing Board
Tage Ramakrishna	Member of Executive Committee
Cees Heiman	Member of Executive Committee
Fernando Zarate	Member of Executive Committee
Graham Jackson	Member of Executive Committee
Jeff Hartness	Member of Executive Committee
Kathleen Fitzpatrick	Member of Executive Committee
Mirza Dautbegovic	Member of Executive Committee
Seana Carson	Member of Executive Committee

Member of Executive

Committee

Tom Vadaketh

Board of directors	
John Paulson	Chairman of Supervisory Board
Amy Wechsler	Member of Supervisory Board
Richard Mulligan	Member of Supervisory Board
Brett Icahn	Member of Supervisory Board
Christian Garcia	Member of Supervisory Board
Frank Lee	Member of Supervisory Board
Robert Power	Member of Supervisory Board
Sarah Kavanagh	Member of Supervisory Board
Steven Miller	Member of Supervisory Board

